Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Backlash: GSK’s Phase II Multiple Sclerosis Drug On Clinical Hold

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK drug is a dual alpha-4 integrin antagonist, the same mechanism of action as Tysabri. Biogen Idec/Elan suspended Tysabri marketing based on a safety signal. GSK had expected to file an NDA for ’699 in 2008.

You may also be interested in...



Novartis's Phase III Program For MS Agent FTY720 Delayed By Safety Request From FDA

Firm previously had projected a mid-year start for Phase III studies of the oral multiple sclerosis treatment. Novartis says the revised timeframe will allow for an FDA-requested safety analysis relating to FTY720's use in renal transplantation.

Novartis's Phase III Program For MS Agent FTY720 Delayed By Safety Request From FDA

Firm previously had projected a mid-year start for Phase III studies of the oral multiple sclerosis treatment. Novartis says the revised timeframe will allow for an FDA-requested safety analysis relating to FTY720's use in renal transplantation.

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel